Related Experiment Video
Updated: Jan 4, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies
Dean G Brown1, Graham F Smith2, Heike J Wobst3
1Hit Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.
Abstract:
We conducted an analysis on screening data generated from 1445 compounds against a panel of 130 enzymes, ion channels, and receptors to assess secondary pharmacological risks. Hit rates of these targets as well as physicochemical properties for those hits were evaluated. A majority of targets yielded hits with higher clogP, molecular weight, and more basic character than inactive compounds. Although most targets favored lipophilic hits, the average clogP of hits at a given target did not correlate with its hit rate. Furthermore, a matched pair analysis was completed to determine structural changes that impacted off-target activities. A correlation of binding assays used in this analysis illustrated that some pharmacologically related binding assays are highly correlative and may be substituted for a smaller set of surrogate assays.
More Related Videos
Related Concept Videos
Drug Discovery: Overview
In Vitro Drug Release Testing: Overview, Development and Validation
Preclinical Development: Overview
Drug Product Performance: In Vitro–In Vivo Correlation
In Vitro Drug Dissolution: Compendial Testing Models II
In Vitro Drug Dissolution: Compendial Testing Models I

